Stock Track | ImmuneOnco Soars on Global Development Plans for Cancer Bispecific Antibody

Stock Track09-16

Shares of ImmuneOnco Biopharmaceuticals Shanghai Inc. surged by nearly 47% on Monday after the company and its partner Instil Bio announced a global registrational strategy for their bispecific antibody SYN-2510/IMM2510, targeting non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC).

The collaboration plans to initiate a Phase 1b/2 trial in late 2024 in China, evaluating SYN-2510/IMM2510 in combination with chemotherapy as a first-line treatment for NSCLC. Additionally, a similar Phase 1b/2 trial in first-line TNBC is anticipated in early 2025 in China.

Furthermore, Instil Bio plans to submit an Investigational New Drug (IND) application for SYN-2510 in the US by late 2024, with the aim of initiating a Phase 2 trial investigating the bispecific antibody as a monotherapy in second-line NSCLC patients.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1115926550?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-16 19:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1115926550","market":"us","top_or_hot":-1,"title":"Stock Track | ImmuneOnco Soars on Global Development Plans for Cancer Bispecific Antibody","media":"Stock Track","content":"<p>Shares of ImmuneOnco Biopharmaceuticals Shanghai Inc. surged by nearly 47% on Monday after the company and its partner Instil Bio announced a global registrational strategy for their bispecific antibody SYN-2510/IMM2510, targeting non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC).</p>\n\n<p>The collaboration plans to initiate a Phase 1b/2 trial in late 2024 in China, evaluating SYN-2510/IMM2510 in combination with chemotherapy as a first-line treatment for NSCLC. Additionally, a similar Phase 1b/2 trial in first-line TNBC is anticipated in early 2025 in China.</p>\n\n<p>Furthermore, Instil Bio plans to submit an Investigational New Drug (IND) application for SYN-2510 in the US by late 2024, with the aim of initiating a Phase 2 trial investigating the bispecific antibody as a monotherapy in second-line NSCLC patients.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | ImmuneOnco Soars on Global Development Plans for Cancer Bispecific Antibody</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | ImmuneOnco Soars on Global Development Plans for Cancer Bispecific Antibody\n</h2>\n\n<h4 class=\"meta\">\n\n2024-09-16 19:30 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of ImmuneOnco Biopharmaceuticals Shanghai Inc. surged by nearly 47% on Monday after the company and its partner Instil Bio announced a global registrational strategy for their bispecific ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01541","symbol_name":"宜明昂科-B","start_time":0,"source_url":"","article_id":"1115926550","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1115926550","pubTimestamp":1726486231,"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of ImmuneOnco Biopharmaceuticals Shanghai Inc. surged by nearly 47% on Monday after the company and its partner Instil Bio announced a global registrational strategy for their bispecific antibody SYN-2510/IMM2510, targeting non-small cell lung cancer  and triple-negative breast cancer .The collaboration plans to initiate a Phase 1b/2 trial in late 2024 in China, evaluating SYN-2510/IMM2510 in combination with chemotherapy as a first-line treatment for NSCLC. Additionally, a similar Phase ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01541":"宜明昂科-B"},"translate_title":"股票追踪ImmuneOnco因癌症双特异性抗体全球开发计划而飙升","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01541":1},"content_text":"Shares of ImmuneOnco Biopharmaceuticals Shanghai Inc. surged by nearly 47% on Monday after the company and its partner Instil Bio announced a global registrational strategy for their bispecific antibody SYN-2510/IMM2510, targeting non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC).\nThe collaboration plans to initiate a Phase 1b/2 trial in late 2024 in China, evaluating SYN-2510/IMM2510 in combination with chemotherapy as a first-line treatment for NSCLC. Additionally, a similar Phase 1b/2 trial in first-line TNBC is anticipated in early 2025 in China.\nFurthermore, Instil Bio plans to submit an Investigational New Drug (IND) application for SYN-2510 in the US by late 2024, with the aim of initiating a Phase 2 trial investigating the bispecific antibody as a monotherapy in second-line NSCLC patients.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.28.1","shortVersion":"4.28.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1115926550"}